Introducing Orgavalue - The 2023 EIT InnoStars Awards winner
Summary
We harness advanced bioengineering techniques, including tissue engineering and stem cell technology, augmented by medical devices, to craft bespoke human organs. In contrast to the less effective immersion decellularization, which compromises the scaffold’s integrity and its vascular system, our perfusion method ensures rapid, non-toxic, and efficient cell removal. These bioengineered organs possess an anatomical structure and extracellular matrix (ECM) composition akin to native tissue, achieved through a sophisticated decellularization process that removes unwanted biological materials, ensuring the scaffold’s integrity which is crucial for successful recellularization. Being part of the EIT Innovation Community has also been transformative, facilitating our integration into a broader ecosystem and enabling us to secure financial and strategic investment from both the private and public sectors, further fueling our advancement What advice would you give to aspiring entrepreneurs looking to enter the biotechnology and health startup space? In a field where the end products are as much about scientific precision as they are about market timing and public reception, the ability to balance these elements is what will define the next wave of biotech success stories.